Table 2.
Analysis of abatacept effectiveness overall, and stratified by line of therapy, and by number of previous failed anti-TNFs
|
Measure |
Baseline |
Change from baseline to month 6 |
||
|---|---|---|---|---|
| N | Mean (SD) | Mean (95% CI) | ||
| |
|
Overall |
|
|
|
DAS28 (ESR) |
539 |
5.5 (1.2) |
473 |
−1.5 (−1.6, –1.3) |
|
DAS28 (CRP) |
151 |
5.2 (1.3) |
113 |
−1.5 (−1.7, –1.2) |
|
CDAI |
647 |
31.7 (13.2) |
605 |
−15.2 (−16.3, –14.1) |
| |
|
First-line |
|
|
|
DAS28 (ESR) |
33 |
5.2 (1.2) |
29 |
−1.7 (−2.3, –1.1) |
|
DAS28 (CRP) |
5 |
4.5 (1.3) |
4 |
−2.0 (−3.2, –0.8) |
|
CDAI |
48 |
31.9 (11.9) |
41 |
−18.3 (−22.0, –14.6) |
| |
|
Second-line |
|
|
|
DAS28 (ESR) |
506 |
5.6 (1.2) |
444 |
−1.5 (−1.6, –1.3) |
|
DAS28 (CRP) |
146 |
5.3 (1.3) |
109 |
−1.4 (−1.7, –1.2) |
|
CDAI |
599 |
31.7 (13.2) |
564 |
−15.0 (−16.1, –13.9) |
| |
|
One previous anti-TNF |
|
|
|
DAS28 (ESR) |
247 |
5.5 (1.2) |
221 |
−1.6 (−1.8, –1.4) |
|
DAS28 (CRP) |
64 |
5.2 (1.3) |
46 |
−1.7 (−2.2, –1.2) |
|
CDAI |
291 |
30.6 (12.7) |
278 |
−15.0 (−16.5, –13.5) |
| |
|
≥2 previous anti-TNFs |
|
|
|
DAS28 (ESR) |
251 |
5.6 (1.3) |
216 |
−1.3 (−1.5, –1.1) |
|
DAS28 (CRP) |
78 |
5.3 (1.4) |
59 |
−1.2 (−1.6, –0.8) |
| CDAI | 295 | 32.5 (13.6) | 275 | −14.7 (−16.4, –12.9) |
CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; LDAS, low disease activity state; SD, standard deviation; TNF, tumor necrosis factor.